M. Jose Camarasa
She received her PhD in Chemistry from the Complutense University of Madrid. After two years of postdoctoral stay at the Department of Medicinal Chemistry in the University of Birmingham (UK), she returned to the Institute of Medicinal Chemistry (CSIC), as postdoctoral (1985-1987). In 1987 she got a permanent position as Tenured Scientist and founded her own independent research group that is now a consolidated and highly prestigious team, composed by permanent staff with complementary profiles of expertise and know-how, and a variable number of postdoctoral and PhD students. In 1993 she was promoted to Research Scientist and since 2002 she is Research Professor (Full Professor).
She has high experience in the Management of Science and Scientific Societies: she was Head of the Chemotherapy Department (1991-1994) and Vice-Director (1992-2001) of the IQM-CSIC; Deputy co-Coordinator of the Science and Chemical Technologies Area of the CSIC (2004-2011); from 2005 to 2010 she was Deputy Member of the Chemistry area of the ANEP (National Evaluation and Foresight Agency) of Spain. She is the Head of the Group “Nucleosides and Analogues”. She was President of the SEQT (Spanish Society of Therapeutic Chemistry), 2004-2007 and board member of International Society of Nucleosides, Nucleotides & Nucleic Acids (IS3NA) (2011-2018).
Member of the editorial board of Journal of Medicinal Chemistry (2013-2016), member by invitation of the panel of the “programme of development of the publication” of Nature (2008-2009) anf of the del “panel reading survey” of Nature (2009-2010). Currently, is on the editorial board of: Nucleosides, Nucleotides and Nucleic Acids, Current Topics in Medicinal Chemistry, ChemMedChem, Current HIV Research, Antiviral Chemistry & Chemotherapy, and has been the “Gest Editor” of a Special issue of Current Topics in Medicinal Chemistry (2004).
She developed a highly innovative cutting-edge research in the Medicinal Chemistry field, working in different therapeutic areas as, (re)emerging viral diseases (i.e. AIDS), parasitic diseases or bacterial and chemotherapy of cancer. She performs her research career in a wide network of international collaborations in Spain, Europe, and the USA with top-laboratories with complementary expertise, skills and know-how. Likewise, she has developed a novel and unique prodrug approach based on the DPPIV/CD26 enzyme.
She is a recipient of a variety of national (private and governmental) and international grants as principal investigator (PI), national and european projects (financed by the EU and NATO) and recently an iNEXT H2020 project (July 2018). She has participated in several international bilateral agreements and in contracts with national and international pharmaceutical companies.
She is author of more than 200 articles in international high impact peer-reviewed journals. Contributed to 6 book chapters and is the Editor of one Book. Co-inventor of 17 patents approved and/or pending, 4 of them licensed. She has supervised 14 PhD thesis.
She received various national and international awards and recognitions, including the prestigious and highly competitive René Descartes Prize 2001 of the European Commission, in recognition of her work in the field of AIDS. In 2009 was Nominated to L’OREAL-UNESCO Award 2009 For Women in Science.